Preclinical assessment of rilzabrutinib on both adaptive and innate immune mechanisms with indications for treatment of a broad array of immune-mediated diseases.

Supporters

Support the authors with ResearchCoin

Tip RSC

Topics

Medicine

Clinical Trials

Immunology

Pharmacology

Bruton'S Tyrosine Kinase

Show all topics

DOI

10.4049/jimmunol.2001130

Other Formats

PDF